Nanosynth Group Plc announced that it has entered into a new Joint Venture Agreement with, inter alia, Volz Holding v.o.s forming the basis upon which the Parties intend to develop, market and sell an anti-pathogenic product for the global filtration market. The Company will initially own 51% of the JV. nanosynth and Volz have each agreed to licence their respective proprietary filtration and manufacturing technologies to the JV for the purpose of producing an anti-pathogen product for the global filtration market. Specifically, P2F have licenced their antipathogenic IP (PCT/GB2021/052733, NANOPARTICLES FOR USE IN ANTI PATHOGENIC APPLICATIONS) to the JV. The JV agreement has been entered into on the basis of an agreed business plan and marketing and sales strategy. Each of the Parties will be represented on the JV board of directors.